Mahamaya Lifesciences Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Mahamaya Lifesciences Limited's achieved publicly listed status following its IPO debut on Nov 18, 2025 at the BSE platform. The offering successfully mobilized 61,78,800 Shares, with 53,29,200 Shares allocated to corporate growth initiatives and ₹6.16 Cr providing liquidity to existing shareholders.
Investment participation occurred within the established price band of ₹108 to ₹114, starting from minimum lots of 1200 shares. The subscription window from Nov 11, 2025 through Nov 13, 2025 enabled investor participation across market segments.
Share allocation was completed on Nov 14, 2025, determining ownership distribution among successful applicants. The listing represents a milestone achievement, transitioning the company to regulated public market status with associated responsibilities and opportunities.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in the manufacturing, registration, and export of high-quality crop protection products and bioproducts designed to enhance soil and crop health. The company specializes in pesticide formulations and supplies bulk products to leading Indian agrochemical players as well as multinational corporations (MNCs). Mahamaya imports global research-based molecules, registers them with the Central Insecticides Board, and markets both technical and value-added formulations. The company has invested significantly in global registrations and currently exports to markets such as the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey. Its portfolio spans bulk formulations, technical grade molecules, branded products, and export-focused formulations.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Experienced Leadership: Managed by a skilled team with deep expertise in agrochemicals, R&D, exports, and regulatory affairs, driving strategic and operational efficiency.
- Comprehensive Product Range: Diverse lineup of insecticides, herbicides, fungicides, and bioproducts across technical, branded, and export formats ensures wide market presence.
- Robust R&D and Regulatory Strength: Strong capability in molecule discovery and registration with Indian and global authorities enhances innovation, compliance, and market expansion potential.
- High Customer Dependence: The company’s revenue relies heavily on a limited number of clients, with the top 10 customers contributing 71.35%, 76.26%, 83.14%, and 71.12% of total sales for the quarter ended June 30, 2025, and fiscal years 2025, 2024, and 2023, respectively, reflecting a notable concentration risk.
- Absence of Long-Term Agreements: The company operates without long-term contracts with customers or suppliers, exposing it to potential fluctuations in demand, pricing, and supply continuity.
- Volatility in Raw Material Costs: As raw materials constitute a significant portion of total expenses, any increase in prices or disruption in availability could adversely affect profitability and operational stability.
- Mr. Krishnamurthy Ganesan
- Mrs. Lalitha Krishnamurthy
- Mr. Prashant Krishnamurthy
Mahamaya Lifesciences Limited
Kfin Technologies Limited